Lucas K Vitzthum1,2, Paul Riviere1, Paige Sheridan1, Vinit Nalawade1, Rishi Deka1, Timothy Furnish3, Loren K Mell1,2, Brent Rose1,2, Mark Wallace, James D Murphy1,2. 1. Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA. 2. Center for Precision Radiation Medicine, University of California San Diego, La Jolla, CA. 3. Department of Family Medicine and Public Health and Division of Pain Medicine, Department of Internal Medicine, University of California San Diego, La Jolla, CA.
Abstract
BACKGROUND: Although opioids play a critical role in the management of cancer pain, the ongoing opioid epidemic has raised concerns regarding their persistent use and abuse. We lack data-driven tools in oncology to understand the risk of adverse opioid-related outcomes. This project seeks to identify clinical risk factors and create a risk score to help identify patients at risk of persistent opioid use and abuse. METHODS: Within a cohort of 106 732 military veteran cancer survivors diagnosed between 2000 and 2015, we determined rates of persistent posttreatment opioid use, diagnoses of opioid abuse or dependence, and admissions for opioid toxicity. A multivariable logistic regression model was used to identify patient, cancer, and treatment risk factors associated with adverse opioid-related outcomes. Predictive risk models were developed and validated using a least absolute shrinkage and selection operator regression technique. RESULTS: The rate of persistent opioid use in cancer survivors was 8.3% (95% CI = 8.1% to 8.4%); the rate of opioid abuse or dependence was 2.9% (95% CI = 2.8% to 3.0%); and the rate of opioid-related admissions was 2.1% (95% CI = 2.0% to 2.2%). On multivariable analysis, several patient, demographic, and cancer and treatment factors were associated with risk of persistent opioid use. Predictive models showed a high level of discrimination when identifying individuals at risk of adverse opioid-related outcomes including persistent opioid use (area under the curve [AUC] = 0.85), future diagnoses of opioid abuse or dependence (AUC = 0.87), and admission for opioid abuse or toxicity (AUC = 0.78). CONCLUSION: This study demonstrates the potential to predict adverse opioid-related outcomes among cancer survivors. With further validation, personalized risk-stratification approaches could guide management when prescribing opioids in cancer patients.
BACKGROUND: Although opioids play a critical role in the management of cancer pain, the ongoing opioid epidemic has raised concerns regarding their persistent use and abuse. We lack data-driven tools in oncology to understand the risk of adverse opioid-related outcomes. This project seeks to identify clinical risk factors and create a risk score to help identify patients at risk of persistent opioid use and abuse. METHODS: Within a cohort of 106 732 military veteran cancer survivors diagnosed between 2000 and 2015, we determined rates of persistent posttreatment opioid use, diagnoses of opioid abuse or dependence, and admissions for opioid toxicity. A multivariable logistic regression model was used to identify patient, cancer, and treatment risk factors associated with adverse opioid-related outcomes. Predictive risk models were developed and validated using a least absolute shrinkage and selection operator regression technique. RESULTS: The rate of persistent opioid use in cancer survivors was 8.3% (95% CI = 8.1% to 8.4%); the rate of opioid abuse or dependence was 2.9% (95% CI = 2.8% to 3.0%); and the rate of opioid-related admissions was 2.1% (95% CI = 2.0% to 2.2%). On multivariable analysis, several patient, demographic, and cancer and treatment factors were associated with risk of persistent opioid use. Predictive models showed a high level of discrimination when identifying individuals at risk of adverse opioid-related outcomes including persistent opioid use (area under the curve [AUC] = 0.85), future diagnoses of opioid abuse or dependence (AUC = 0.87), and admission for opioid abuse or toxicity (AUC = 0.78). CONCLUSION: This study demonstrates the potential to predict adverse opioid-related outcomes among cancer survivors. With further validation, personalized risk-stratification approaches could guide management when prescribing opioids in cancerpatients.
Authors: Hude Quan; Vijaya Sundararajan; Patricia Halfon; Andrew Fong; Bernard Burnand; Jean-Christophe Luthi; L Duncan Saunders; Cynthia A Beck; Thomas E Feasby; William A Ghali Journal: Med Care Date: 2005-11 Impact factor: 2.983
Authors: Amy S B Bohnert; Mark A Ilgen; Jodie A Trafton; Robert D Kerns; Anna Eisenberg; Dara Ganoczy; Frederic C Blow Journal: Clin J Pain Date: 2014-07 Impact factor: 3.442
Authors: Stephen F Butler; Kathrine Fernandez; Christine Benoit; Simon H Budman; Robert N Jamison Journal: J Pain Date: 2008-01-22 Impact factor: 5.820
Authors: Judith A Paice; Russell Portenoy; Christina Lacchetti; Toby Campbell; Andrea Cheville; Marc Citron; Louis S Constine; Andrea Cooper; Paul Glare; Frank Keefe; Lakshmi Koyyalagunta; Michael Levy; Christine Miaskowski; Shirley Otis-Green; Paul Sloan; Eduardo Bruera Journal: J Clin Oncol Date: 2016-07-25 Impact factor: 44.544
Authors: Derrick C Gibson; Mukaila A Raji; Holly M Holmes; Jacques G Baillargeon; Yong-Fang Kuo Journal: Mayo Clin Proc Date: 2022-02-05 Impact factor: 7.616
Authors: Lucian Zhao; Dominic H Moon; Vladimir Avkshtol; Caitlin H Siropaides; Stephanie Terauchi; Andrew T Day; Baran D Sumer; Randall Hughes; David J Sher Journal: Support Care Cancer Date: 2022-06-06 Impact factor: 3.359
Authors: Lucas K Vitzthum; Vinit Nalawade; Paul Riviere; Mallika Marar; Timothy Furnish; Lewei A Lin; Reid Thompson; James D Murphy Journal: J Natl Cancer Inst Date: 2022-05-09 Impact factor: 11.816
Authors: Lucas K Vitzthum; Vinit Nalawade; Paul Riviere; Whitney Sumner; Tyler Nelson; Loren K Mell; Timothy Furnish; Brent Rose; María Elena Martínez; James D Murphy Journal: JCO Oncol Pract Date: 2021-02-03
Authors: Dinorah Martinez Tyson; Melody N Chavez; Paige Lake; Ana Gutierrez; Peggie Sherry; Khary K Rigg; Victoria K Marshall; Heather Henderson; Barbara Lubrano di Ciccone; Sahana Rajasekhara; Smitha Pabbathi Journal: J Cancer Surviv Date: 2021-01-06 Impact factor: 4.062
Authors: Benjamin D Hallowell; Laura C Chambers; Luke Barre; Nancy Diao; Collette Onyejekwe; Alexandra Banks; Jeffery Bratberg; Heidi Weidele; Samara Viner-Brown; James McDonald Journal: BMJ Open Date: 2022-01-06 Impact factor: 2.692